8-K: GeneDx Reports Strong Q1 2025 Results, Announces Fabric Genomics Acquisition, and Raises Full Year Guidance

GeneDx reports a successful first quarter in 2025 with significant revenue growth, profitability, and the announcement of the acquisition of Fabric Genomics, leading to raised full-year revenue guidance.

Summary

• GeneDx Holdings Corp. reported its financial results for the first quarter of 2025.
• Revenues grew to $87.1 million, a 42% year-over-year increase.
• Exome and genome test revenue increased by 62% year-over-year to $71.4 million.
• Exome and genome test results volume grew by 24% year-over-year to 20,562.
• Adjusted gross margin was 69%, compared to 61% in the first quarter of 2024.
• Adjusted net income was $7.7 million, a significant improvement from the $8.0 million adjusted net loss in the first quarter of 2024.
• The company's cash position, including cash equivalents, marketable securities, and restricted cash, was $160.2 million as of March 31, 2025.
• GeneDx has updated its full-year 2025 revenue guidance to between $360 and $375 million, including a $3 to $5 million contribution from the planned acquisition of Fabric Genomics.
• The company reaffirmed its outlook for at least 30% growth in exome/genome volume and revenue for FY 2025.
• Adjusted gross margins are expected to be between 66% and 68% for the full year.
• GeneDx anticipates profitability with adjusted net income each quarter and for the full year 2025.
• The company announced plans to acquire Fabric Genomics for $33 million upfront, with potential total consideration reaching up to $51 million based on achieving certain revenue and gross margin targets in FY2025 and FY2026.
• The acquisition is expected to close in the second quarter of 2025.
• GeneDx launched ultraRapid Whole Genome Sequencing, offering accelerated genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as 48 hours.
• The company launched Epic Aura, integrating GeneDx exome and genome testing into health systems' workflows.
• GeneDx expanded its commercial footprint for exome and genome testing with cerebral palsy (CP) and Inborn Errors of Immunity (IEIs) as new indications.
• The company highlighted the results of the first 10,000 participants enrolled in the GUARDIAN study, demonstrating the feasibility of screening for a targeted set of genes in a diverse newborn population with genomic newborn screening (gNBS).
• GeneDx announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, strategic acquisitions, and innovative product launches. The company's growth trajectory and market position are promising, justifying a high sentiment score.

Positives

• Significant revenue growth of 42% year-over-year in Q1 2025.
• Strong growth in exome and genome test revenue, increasing by 62% year-over-year.
• Return to profitability with adjusted net income of $7.7 million in Q1 2025.
• Improved adjusted gross margin of 69% compared to 61% in the same quarter last year.
• Raised full-year revenue guidance, indicating confidence in future performance.
• Strategic acquisition of Fabric Genomics to expand market reach and capabilities.
• Launch of innovative products like ultraRapid Whole Genome Sequencing.
• Strong cash position providing financial flexibility.
• Expanded coverage by state Medicaid programs for exome and genome sequencing.
• Launch of Epic Aura to streamline testing workflows.

Negatives

• GAAP net loss of $6.5 million for the quarter, although this is an improvement from the previous year.
• Total GAAP operating expenses were $63.0 million.
• The company still relies on non-GAAP measures to present a more favorable financial picture.

Risks

• The company's ability to successfully integrate Fabric Genomics.
• The risk of downturns and a changing regulatory landscape in the healthcare industry.
• The company's ability to enhance its artificial intelligence tools.
• The company's ability to implement business plans, goals and forecasts, and identify and realize additional opportunities.
• The size and growth of the market in which we operate.
• The company's ability to pursue our new strategic direction.

Future Outlook

GeneDx expects to deliver revenues between $360 to $375 million for full year 2025, inclusive of $3 to $5 million in post-close revenue contribution from the planned acquisition of Fabric Genomics, assuming a second quarter 2025 close. The company also expects growth in exome/genome volume and revenue of at least 30%, adjusted gross margins between 66%-68%, and profitability with adjusted net income each quarter and for full year 2025.

Management Comments

• Katherine Stueland, CEO of GeneDx, stated that healthcare is at an inflection point where integrating genomic insights into standard care is becoming essential.
• Katherine Stueland noted that the first quarter exceeded expectations across all measures, with 62% revenue growth in exome/genome and the third consecutive quarter of profitability.
• Kevin Feeley, CFO of GeneDx, mentioned that the business continued to exceed expectations, with volume growth accelerating throughout the quarter.
• Kevin Feeley stated that the combination of continued core momentum, the rolling expansion of new indications in the outpatient setting, and the recent launch of a new ultraRapid genome product are expected to drive incremental volume growth opportunities throughout the remainder of 2025 and beyond.

Industry Context

GeneDx's focus on genomic insights and its acquisition of Fabric Genomics align with the broader industry trend of integrating genomics into standard healthcare. The company's expansion into new indications like cerebral palsy and Inborn Errors of Immunity reflects the growing recognition of the importance of genetic testing in diagnosing and treating various conditions. The emphasis on rapid genome sequencing and AI-powered decision support tools highlights the industry's move towards faster, more efficient, and more accurate genetic analysis.

Comparison to Industry Standards

• The 62% year-over-year growth in exome and genome test revenue significantly outpaces the average growth rate for the molecular diagnostics market, which is typically in the single to double-digit percentages.
• The adjusted gross margin of 69% is competitive with other leading genetic testing companies, such as Exact Sciences and Myriad Genetics, which typically report gross margins in the 70-80% range.
• The launch of ultraRapid Whole Genome Sequencing with a 48-hour turnaround time positions GeneDx as a leader in the rapid genomic testing space, competing with companies like Rady Children's Institute for Genomic Medicine.
• The GUARDIAN study, with over 17,000 healthy newborns screened, is one of the largest genomic newborn screening initiatives, comparable to projects like the BabySeq Project at Brigham and Women's Hospital and Boston Children's Hospital.
• The acquisition of Fabric Genomics is a strategic move similar to other acquisitions in the genomics space, such as Illumina's acquisition of GRAIL, aimed at expanding market reach and capabilities.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and growth prospects.
• Employees will have opportunities for growth and development within the expanding company.
• Customers (patients and healthcare providers) will have access to more advanced and efficient genomic testing solutions.
• Suppliers will benefit from increased demand for genomic testing services.
• The healthcare system as a whole will benefit from improved diagnostic accuracy and more efficient healthcare spending.

Next Steps

• Close the acquisition of Fabric Genomics in the second quarter of 2025.
• Integrate Fabric Genomics' platform and capabilities into GeneDx's offerings.
• Continue expanding commercial footprint for exome and genome testing with new indications.
• Further develop and enhance AI-powered decision support tools.
• Drive adoption of ultraRapid Whole Genome Sequencing in NICUs and PICUs.
• Expand coverage by state Medicaid programs for exome and genome sequencing.
• Launch additional solutions for biopharma.

Key Dates

Keywords

GeneDx, genomics, exome sequencing, genome sequencing, Fabric Genomics, financial results, revenue, adjusted net income, gross margin, acquisition, guidance, genomic testing, molecular diagnostics